Bio3 Research and Creabilis Therapeutics Sign Research Agreements with Cephalon, Inc
Released on = November 30, 2005, 2:35 am
Press Release Author = Anna Oderda
Industry = Biotech
Press Release Summary = Research Will Focus on Potential New Treatments for
Psoriasis and Restenosis
Press Release Body = Colleretto Giacosa (Turin) Italy, and Milan Italy, November 30,
2005- Bio3 Research s.r.l., and
Creabilis Therapeutics S.p.A. today announced agreements with Cephalon, Inc. to
evaluate the research
compound K252a for its potential to topically treat psoriasis and for potential use
in the prevention and
treatment of restenosis. Creabilis Therapeutics owns patent applications covering
K252a-based products
for the treatment of psoriasis.
Bio3 Research and Creabilis Therapeutics co-own a patent application covering the
use of K252a compound to prevent and treat restenosis and other cardiovascular disorders. Cephalon has proprietary rights in
certain production processes for the compound. Also, with respect to the prevention
and treatment of
restenosis, Bio3 Research retains the right to collaborate with third parties in
combining K252a with drugeluting
stents. Other terms of the agreements were not disclosed.
Under the agreement, Cephalon has an exclusive option to develop and commercialize
K252a-based
products that may result from research performed by Creabilis Therapeutics and Bio3
Research.
"This agreement with Cephalon is a great opportunity for Creabilis Therapeutics because it enables us to
accelerate the development process of this promising compound," said Dr. Silvano Fumero, the company's
CEO. "We expect to file the INDs by the end of 2006."
Francesco Paolo Pilato, President and CEO of Bio3 Research, said, "We are delighted
to have entered into
this agreement with Cephalon, and we believe it is a great opportunity for our
company to accelerate the
ongoing development process at Creabilis Therapeutics. This research is part of
Bio3's strong IP position in
the field of HMGB1-related cardiovascular disorders."
About Creabilis Therapeutics S.p.A.
Creabilis Therapeutics S.p.A. is a privately owned drug-discovery and development
company, founded in
2003 and located in the Bioindustry Park of Canavese, near Turin. The company's
activity focuses mainly on
DNA-binding proteins, such as HMGB1, as pharmacological targets for novel classes of
inhibitors/antagonists to be developed as therapeutics. This portfolio is
complemented by selected projects in
related biochemical or clinical areas. Additional information on Creabilis Therapeutics can be obtained from
www.creabilistherapeutics.com or by e-mail: info@creabilistherapeutics.com
About Bio3 Research s.r.l.
Bio3 Research s.r.l., an Italian company founded in 2001, has headquarters in Milan
and an office at the
Bioindustry Park of Canavese (Turin). Bio3 Research works with research
institutions, individual scientists
and early-stage companies to identify, protect and exploit commercially promising
intellectual property in the
life sciences. Such assistance may include pre-clinical development and negotiation
of strategic industrial
partnerships. Bio3 Research's activity focuses mainly on the field of HMBG1-related
cardiovascular disorders
and use of HMGB1 and its fragments in connective tissue regeneration. Other fields
of interest include skin
and renal diseases. Additional information on Bio3 Research can be obtained from
www.bio3research.com
or by e-mail: info@bio3research.com
2025
